Switch Maintenance Gemcitabine after First Line Chemotherapy in Patients with Malignant Mesothelioma: A Randomized Open Label Phase II Trial (NVALT19)

Autor: Magdolen Youssef-El Soud, Paul Baas, Jos A. Stigt, Nico van Walree, Harry J.M. Groen, Harm van Tinteren, Ferry Lalezari, Nvalt Study Team, Robbert C. van Heemst, Jacobus A. Burgers, Wieneke A. Buikhuisen, Cornedine J. de Gooijer, Agnes J. Staal-van den Brekel, Bonne Biesma, Joachim G.J.V. Aerts, Vincent van der Noort, Gerben Bootsma, Floris Dammeijer, Robin Cornelissen

Publikováno v: SSRN Electronic Journal.

Background: All patients with malignant mesothelioma develop progressive disease after first line therapy. Some studies have addressed maintenance therapy, none showed a great impact. Gemcitabine, an active drug in mesothelioma, was tested in the NVA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e7f7e7d9fa2908b5b66340540efb393
https://doi.org/10.2139/ssrn.3520057

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer

Autor: Gerarda J.M. Herder, Agnes J. Staal-van den Brekel, Joachim G.J.V. Aerts, Anne-Marie C. Dingemans, Tjeerd Haitjema, Michel M. van den Heuvel, Lizza E.L. Hendriks, Egbert F. Smit, Ben E. E. M. van den Borne, A. Termeer, Martijn J. Goosens, Lucie Masen-Poos, Robbert C. van Heemst, Frans H. Krouwels, Jos A. Stigt, E. Pouw, Wouter W. Mellema, Hans J.M. Smit, Anthonie J. van der Wekken

Publikováno v: Lung Cancer, 90(2), 249-254. Elsevier Ireland Ltd
Lung Cancer, 90(2), 249-254. ELSEVIER IRELAND LTD
Mellema, W W, Masen-Poos, L, Smit, E F, Hendriks, L E L, Aerts, JG, Termeer, A, Goosens, M J, Smit, H J M, van den Heuvel, M M, van der Wekken, A J, Herder, G J M, Krouwels, F H, Stigt, J A, van den Borne, B E E M, Haitjema, T J, Staal-Van Den Brekel, A, van Heemst, R C, Pouwq, E & Dingemans, A M C 2015, ' Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer ', Lung Cancer, vol. 90, no. 2, pp. 249-254 . https://doi.org/10.1016/j.lungcan.2015.09.012

Objectives: As suggested by in-vitro data, we hypothesize that subtypes of ICRAS mutated non-small cell lung cancer (NSCLC) respond differently to chemotherapy regimens.Methods: Patients with advanced NSCLC and known KRAS mutation, treated with first

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1fdfbe6a52fbb09bb6db5676889a236
https://research.vumc.nl/en/publications/84cfc5c1-2095-483b-a182-e57eb74efbfb